Recent Updates
Recently added Catalysts

ALLOB cells with ceramic scaffold

Phase 2

Degenerative Disc Disease | Small molecule | Musculoskeletal |Bone Biologics Corp|Last Updated: Jan 29, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment38

FDA Designations

No designations recorded

Clinical trial landscape

ALLOB cells with ceramic scaffold · 1 trial · 1 indication

Phase 2 1
NCT02205138Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal FusionDegenerative Disc Disease
COMPLETED38 Analytics
PHASE2COMPLETED
Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion
Degenerative Disc DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

Lumbar fusion progression as assessed by CT scan
12 months
Functional Disability using Oswestry Disability Index
12 months
Potential occurrence of any AE or SAE, related to the product or to the procedure, using patient open non-directive questionnaire, physical examination and laboratory measurements
12 months

Secondary Endpoints

Pain using a Visual Analogue Scale
12 months
Global Disease Evaluation using a Visual Analogue Scale
12 months
Functional Disability using Oswestry Disability Index
12 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ALLOB® cells with ceramic scaffoldEXPERIMENTALALLOB® cells with ceramic scaffold Implantation

Interventions

NameTypeDescription
ALLOB® cells with ceramic scaffoldDRUGEach patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria: * Ability to provide a written, dated, and signed informed consent prior to any study related procedure, and to understand and comply with study requirements * Symptomatic degenerative disc disease of the lumbar spine requiring a single level lumbar fusion (L1-S1) * Unresponsive...

Countries:Belgium
Unlock Eligibility Criteria

Frequently asked questions about ALLOB cells with ceramic scaffold

What is ALLOB cells with ceramic scaffold used for?

ALLOB cells with ceramic scaffold is an investigational cell therapy being studied for the treatment of Degenerative Disc Disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.

Who is developing ALLOB cells with ceramic scaffold?

ALLOB cells with ceramic scaffold is being developed by Bone Biologics Corp, a company listed on the NASDAQ under the ticker symbol BBLG.

What phase is ALLOB cells with ceramic scaffold in?

ALLOB cells with ceramic scaffold is in Phase 2 clinical development. It is an investigational therapy and has not yet received regulatory approval for any indication.

What clinical trials is ALLOB cells with ceramic scaffold in?

ALLOB cells with ceramic scaffold has one completed clinical trial, NCT02205138, a Phase 2a study on allogeneic osteoblastic cells implantation in lumbar spinal fusion. The trial enrolled 38 participants with Degenerative Disc Disease in Belgium.

What does ALLOB cells with ceramic scaffold target?

ALLOB cells with ceramic scaffold is a cell therapy that uses allogeneic osteoblastic cells, which are bone-forming cells, combined with a ceramic scaffold. It is being studied for its potential to promote bone formation in lumbar spinal fusion for Degenerative Disc Disease.